Abstracts Archive - Page 170 of 2607 - ACR Meeting Abstracts

Abstract Number: 0639 • ACR Convergence 2025
Kidney Transplantation In Lupus Nephritis. Multicenter Study Of 103 Patients
Vanesa Calvo-Río¹, Lara Sánchez Bilbao¹, Carmen Secada-Gómez¹, Paúl Hernández Velasco², Celia González-García³, Enrique Morales⁴, María Galindo-Izquierdo⁵, Sebastián Sandoval-Moreno⁶, Josefina Cortés-Hernández⁷, César Antonio Egües Dubuc⁸, Niccolo Viveros-Pérez⁹, María Caeiro¹⁰, Adrián Mayo-Juanatey¹¹, Miriam Retuerto Guerrero¹², María Camila Osorio-Sanjuan¹³, Luis Sala¹⁴ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Nephrology, Hospital Universitario ¹² de Octubre, Madrid. Spain, Madrid, Madrid, Spain, ³Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Madrid, Spain, ⁴Nephrology, Hospital Universitario ¹² de Octubre, Madrid, Madrid, Spain, ⁵Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ⁶Hospital Universitario Vall D'Hebron, Barcelona, Spain, ⁷Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, ⁸Donostia University Hospital, San Sebastián, Pais Vasco, Spain, ⁹Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ¹⁰Centro Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ¹¹Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, ¹²Complejo Asistencial Universitario de León, Leon, Castilla y Leon, Spain, ¹³Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹⁴Hospital Universitario de Torrejón, Madrid, Spain
Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE) affecting to 40-60% of SLE. End-stage renal disease (ESRD) occurs in up…
Abstract Number: 1032 • ACR Convergence 2025
Exploring the role of the gut microbiome in gout: Prospective analysis of dietary fiber intake and the risk of gout
Sharan Rai¹, Natalie McCormick², Chio Yokose³, Robert Terkeltaub⁴, Dylan Dodd⁵, Lama Nazzal⁶, Huilin Li⁶, Qi Sun⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital/Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Waltham, MA, ⁴Retired, San Diego, CA, ⁵Stanford University, Palo Alto, CA, ⁶NYU Langone, New York, NY, ⁷Harvard T.H. Chan School of Public Health, Boston, ⁸MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: The role of the gut microbiome has been increasingly implicated in the pathogenesis of gout. For instance, gout patients have shown depletions of bacteria…
Abstract Number: 1013 • ACR Convergence 2025
All roads lead to Rheum? Modeling scenarios of new patients-to-pediatric rheumatologist ratios in different US states
Gabriela Accetta Rojas¹, Evan Mulvihill², Salma Siddique¹ and Annemarie Brescia¹, ¹Nemours Children's Hospital of Delaware, Wilmington, DE, ²Nemours/A.I.duPont Hospital for Children, Wilmington, DE
Background/Purpose: Rheumatology is among the pediatric subspecialties with the lowest workforce density in the US1. Initial management of most of the pediatric rheumatologic conditions relies…
Abstract Number: 0480 • ACR Convergence 2025
Efficacy and safety of tacrolimus and its serum concentration in patients with rheumatoid arthritis with inadequate response to methotrexate
Chan-Bum Choi, Hanyang University Hosptial for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Addition of a biologic disease-modifying antirheumatic drug (bDMARD) or targeted synthetic DMARD (tsDMARD) is recommended in patients with rheumatoid arthritis (RA) with inadequate response…
Abstract Number: 1052 • ACR Convergence 2025
“Prednisone… A Necessary Evil…” Developing an Evidence-Based Benefits vs. Harms Shared Decision-Making Tool (PRED-SAFE) to Support Decisions Around Chronic Prednisone Use
Isabella Hartel¹, Jay Patel¹, Justin Levinson¹, Sancia Ferguson², Carmen Campbell¹, Amannda Weber³, Shelby Gomez⁴, David Gazeley⁵, Ali Duarte-Garcia⁶, Jennifer Barton⁷ and Shivani Garg⁸, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, Madison, WI, ³University of Wisconsin (UW), UW Health, Madison, WI, ⁴University of Wisconsin, School of Pharmacy, Madison, WI, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Mayo Clinic, Rochester, MN, ⁷VA Portland Health Care System/OHSU, Portland, OR, ⁸University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Guidelines recommend limiting chronic prednisone use ( >5 mg/d for >3-6 mos.) given higher risks of fractures, infections, and damage. Yet, patients struggle to…
Abstract Number: 0500 • ACR Convergence 2025
Is Methotrexate Tapering Possible In Stable RA? Clinical Observations of Methotrexate Tapering At Two Tertiary Care Centers
Sama Hajizadeh¹, Tarun Sharma¹, Peri Newman², Julio Hernandez², Rayford June³, Erik Lehman², Nicole Wilson¹, Nancy Olsen⁴ and Sharon Banks⁵, ¹Allegheny Health Network, Pittsburgh, PA, ²Penn State Health/ Penn State College of Medicine, Hershey, PA, ³Penn State College of Medicine/Lebanon VA Medical Center, Hummelstown, PA, ⁴Penn State University/Milton S Hershey, Hershey, PA, ⁵Penn State Milton S. Hershey Medical Center, Hershey, PA
Background/Purpose: In our previous Rheumatoid Arthritis Medication TAPering (RheumTAP) cohort study of patients with stable RA in remission on biologics +/- methotrexate at Allegheny Health…
Abstract Number: 0939 • ACR Convergence 2025
Exploring the Mechanism of Action and Related Biomarkers of BTK Inhibitor/Degrader in Systemic Lupus Erythematosus
Chengfeng Xue¹, Jingjing Wang¹, Mengwen Huang¹, Ting Liu¹, Panpan Wang¹, Donghai Chen², Xue Wang¹, Yawei Xu¹, Yajun Gong¹, Jun Yang¹, Xiaoshan Yu¹, Ke Wang¹, Yuqing Zhu¹, Kaixuan Zhu¹, Tianqi Tang¹, Wantong Qi¹, Yaqiong Pei¹, Qiyao Zhang¹, Fugang Li², Qingyang Gu¹ and Xiangnan Qiang¹, ¹WuXi AppTec, Shanghai, China (People's Republic), ²WuXi ApptTec, Shanghai, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse clinical and immunological manifestations. Bruton’s tyrosine kinase (BTK) is a crucial intracellular kinase in…
Abstract Number: 1053 • ACR Convergence 2025
Trends in Cost and Utilization of Biologic Medications for Rheumatologic Conditions: A Medicare Claims Study (2013–2022)
Taylor Koenig, Cleveland Clinic, Rocky River, OH
Background/Purpose: Biologic therapies have transformed rheumatologic disease management over the past two decades. As utilization of these high-cost medications increases and additional biologic and biosimilar…
Abstract Number: 0015 • ACR Convergence 2025
CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases
Philipp Richle, Stephanie Jungmichel, Alessio Vantellini, André Fonseca, Anna Howald, Fabian Scheifele, Loredana iuliano, Ariadna Vilarrasa, Romina Doerig, Hannes Merten, Philip Knobel, Daniel Lenherr-Frey, Christian Leisner and Leonardo Borras, CDR-Life, Horgen, Zurich, Switzerland
Background/Purpose: B cells and plasma cells are central to the pathogenesis of many autoimmune diseases. While B cell depletion therapies (BCDTs), such as anti-CD20 monoclonal…
Abstract Number: 1062 • ACR Convergence 2025
Sex-related differences in clinical presentation and patient-reported burden in chronic back pain: Are these findings specific to axSpA? Results from the SHERPAS Cohort
Diego Benavent¹, Mar Tapia², Daniel Bernabeu², Victor Muley², Manuel Juárez³, Alejandro Balsa⁴, Chamaida Plasencia-Rodríguez⁴ and Victoria Navarro-Compan⁵, ¹Hospital Universitari de Bellvitge, Madrid, Spain, ²HU La Paz, Madrid, Spain, ³Rheumatology Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain
Background/Purpose: Sex-related differences in axial spondyloarthritis (axSpA) have been described regarding clinical features, disease burden, and particularly patient-reported outcomes. These differences influence patient management, including…
Abstract Number: 0654 • ACR Convergence 2025
Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial
Ed Vital¹, Benni Vargas², Julie Rae², Tracey Wang³, Jason Hackney², Cary Looney⁴, William Pendergraft², Liz Lightstone⁵, Brad Rovin⁶, Richard Furie⁷ and Harini Raghu², ¹University of Leeds, Leeds, England, United Kingdom, ²Genentech, Inc., South San Francisco, CA, ³Hoffmann-La Roche Ltd, Missssauga, ON, Canada, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁵Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁶The Ohio State University, Columbus, OH, ⁷Division of Rheumatology, Northwell Health, Great Neck, NY
Background/Purpose: Lupus nephritis (LN) is characterized by kidney inflammation. B cells play a central role in LN pathogenesis and type I interferon (IFN-I) pathway activation…
Abstract Number: 1066 • ACR Convergence 2025
Assessing Disparities in Outcomes and Processes of Care for Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
Julia Harris¹, Catherine Bingham², Sheetal Vora³, Jon Burnham⁴, Cagri Yildirim-Toruner⁵, Tzielan Lee⁶, Kerry Ferraro⁷, Erik Friedrichsen⁸, Katelyn Banschbach⁹, Michelle Batthish¹⁰, Danielle Fair¹¹, Mileka Gilbert¹², Beth Gottlieb¹³, Melissa Mannion¹⁴, Edward Oberle¹⁵, Nancy Pan¹⁶, Natalie Rosenwasser¹⁷, Mary Toth¹⁸, Jennifer Weiss¹⁹ and Esi Morgan¹⁷, ¹Children's Mercy Kansas City, Overland Park, KS, ²Penn State Children's Hospital, Hershey, PA, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Children's Hospital of Philadelphia, Bryn Mawr, PA, ⁵Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁶Stanford University School of Medicine, Palo Alto, CA, ⁷Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, ⁸Seattle Children's Hospital, Burien, WA, ⁹cincinnati Children's hospital, Villa Hills, KY, ¹⁰McMaster Children's Hospital, Hamilton, ON, Canada, ¹¹Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, ¹²Medical University of South Carolina, Charleston, SC, ¹³Cohen Children's Medical Center, Northwell Health, Lake Success, NY, ¹⁴University of Alabama at Birmingham, Birmingham, AL, ¹⁵Nationwide Children's Hospital, Columbus, OH, ¹⁶Hospital for Special Surgery, New York, NY, ¹⁷Seattle Children's Hospital, seattle, WA, ¹⁸Nemours Foundation, Orlando, FL, ¹⁹Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) has a mission to deliver exceptional and equitable health care to children with rheumatic diseases…
Abstract Number: 1074 • ACR Convergence 2025
Racial Disparities in Cardiovascular, Ocular, and Treatment Outcomes in US Patients with Behçet’s Disease: A Propensity-Matched Real-World Analysis
Michael Hamilton¹, Justin Riley Lam², Emmanuel Otabor³, Laith Alomari³, Maxim Barnett³, Shahrzad Abdollahi² and Irene Tan⁴, ¹Jefferson Einstein Hospital, Philadelphia, Philadelphia, PA, ²Jefferson Einstein Hospital, Philadelphia, PA, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Racial/ethnic disparities in Behçet’s disease (BD) outcomes are largely undocumented in the United States. Given known differences in disease expression across populations globally, we…
Abstract Number: 0485 • ACR Convergence 2025
Multicenter study on the use of Upadacitinib: Results in RA patients previously treated with Baricitinib
Guillermo Gonzalez Mozo de Rosales¹, Luis Maria Lopez-Dominguez², Nerea Alcorta-Lorenzo³, oihane ibarguengoitia Barrena⁴, David Montero⁵, Ana Ruibal Escribano⁶, estibaliz barastay Alberdi⁷, Jesus Alejandro Valero Jaimes⁸, Libe Ibarrola⁹, Paula Garcia Escudero¹⁰, Marta Lopez I Gomez¹¹, Eva Galindez Aguirregoicoa¹² and Maria Luz Garcia Vivar¹³, ¹Basurto University Hospital, Bilbao, Spain, ²Rheumatology Department, Donostia University Hospital., San Sebastián, Pais Vasco, Spain, ³Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ⁴Galdakao-Usansolo University Hospital, GALDAKAO, Spain, ⁵Galdakao-Usansolo University Hospital, Bilbao, Spain, ⁶Urduliz Hospital, Urduliz, Pais Vasco, Spain, ⁷Urduliz Hospital, Urduliz, Spain, ⁸Hospital Bidasoa, Irán, Spain, ⁹Galdakao-Usansolo University Hospital, Galdakao, ¹⁰H.U.Araba, Vitoria, ¹¹Araba University Hospital, Vitoria, Pais Vasco, Spain, ¹²Basurto University Hospital, Bilbao, Pais Vasco, Spain, ¹³Basurto Hospital, Bilbao, Spain
Background/Purpose: Rheumathoid Arthritis (RA) is a chronic inflammatory disease that affects the musculoskeletal system. Early and effective treatment is important to improve the quality of…
Abstract Number: 1063 • ACR Convergence 2025
Gender, Racial, and Geographic Trends in Mortality from Interstitial Lung Diseases Among Patients With Rheumatoid Arthritis in the U.S. Population, 1999–2020
Farheen Malik¹, Jawad Ahmed², Mandar Shah¹, Ritika Uttam³ and Muhammad Fahimuddin¹, ¹Jacobi Medical Center, Bronx, NY, NY, ²Northwest Health Porter, Valpraiso, IN, ³Jacobi Medical Center, Bronx, NY
Background/Purpose: Rheumatoid arthritis (RA) is a common autoimmune disease affecting up to 1.0% of the US population. RA is most commonly associated with synovial inflammation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].